Clinical outcomes of Bowman-Stromal inlay and corneal collagen crosslinking in contralateral eyes in patients with progressive keratoconus

进行性圆锥角膜患者对侧眼行鲍曼-基质植入术和角膜胶原交联术的临床结果

阅读:1

Abstract

PURPOSE: This study aims to report the outcomes of Bowman-Stromal Inlay (BSI) versus corneal collagen crosslinking (CXL) in patients with progressive keratoconus. METHODS: A retrospective, nonrandomized, interventional, comparative study included 16 patients (n = 32 eyes) with bilateral keratoconus. We analyzed the medical records of patients who had undergone CXL in one eye and BSI in the other, with a minimum follow-up period of 12 months. The medical records were reviewed for outcomes in the form of refractive and tomographic parameters. RESULTS: A total of 16 patients (32 eyes; 16 CXL, 16 BSI) were included in the study. The mean follow-up period was 30.64 ± 6.14 months in the CXL group and 29.5 ± 5.9 months in the BSI group (range: 6 - 61 months). The visual improvement after surgery was better in the BSI group compared to the CXL group, although the changes were not statistically significant (P (UCVA) = 0.25, P (BCVA) = 0.56). No change was observed in the post-operative Kmax and Kmean values throughout the follow-up period in both groups. The postoperative corneal thickness increased significantly in the BSI group (P < 0.001), while it remained unchanged in the CXL group (P = 0.14). After these initial postoperative changes, the pachymetry remained stable throughout the follow-up period. The BSI group showed a significant improvement in asphericity (P = 0.02) postoperatively, whereas asphericity remained unchanged after CXL (P = 0.89). Topographic astigmatism did not show significant changes in either group after surgery compared to the preoperative values. Neither group had any eyes showing the progression of tomographic parameters. CONCLUSION: Both CXL and BSI demonstrated efficacy in preventing the progression of ectasia in keratoconus. BSI showed additional benefits of improved asphericity and increased pachymetry compared to CXL.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。